Kate Lathrop
YOU?
Author Swipe
View article: Pilot phase <scp>II</scp> study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors
Pilot phase <span>II</span> study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors Open
This pilot phase II study evaluated the combination of lenvatinib, a multi‐kinase inhibitor, and eribulin, a microtubule inhibitor, in patients with advanced solid tumors, including breast carcinoma, lung carcinoma, and sarcoma. Tumor angi…
View article: An Introductory Course on Geriatric Oncology
An Introductory Course on Geriatric Oncology Open
Course content was successfully implemented into the hematology/oncology and geriatric medicine fellowship core curriculum using the above methods. Future directions include presentation of course material to incoming trainees, content ref…
View article: Student Perspectives on the Undergraduate Medical Student Research Experience at a Single United States Allopathic Institution
Student Perspectives on the Undergraduate Medical Student Research Experience at a Single United States Allopathic Institution Open
Introduction The purpose of this study was to identify student-reported institutional facilitators and barriers to successful research experiences at a single United States allopathic institution. Residency applications have increasingly b…
View article: CTNI-10. SACITUZUMAB GOVITECAN FOR BREAST CANCER BRAIN METASTASIS
CTNI-10. SACITUZUMAB GOVITECAN FOR BREAST CANCER BRAIN METASTASIS Open
Breast cancer brain metastasis (BCBM) is a challenge that significantly impacts patient prognosis and quality of life. Sacituzumab govitecan (SG), an antibody-drug conjugate, has demonstrated antitumor activity and is approved for triple n…
View article: mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers
mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers Open
Background Mammary physiology is distinguished in containing adult stem/progenitor cells that are actively amending the breast tissue throughout the reproductive lifespan of women. Despite their importance in both mammary gland development…
View article: Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study Open
Background: Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations. Methods: This is a COVID-19 and Cancer Consortium (CCC1…
View article: Author response: Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
Author response: Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study Open
Full text Figures and data Side by side Abstract Editor's evaluation Introduction Methods Results Discussion Appendix 1 Appendix 2 Appendix 3 Appendix 4 Appendix 5 Appendix 6 Appendix 7 Appendix 8 Appendix 9 Data availability References De…
View article: Poziotinib Treatment in Patients With HER2-Positive Advanced Breast Cancer Who Have Received Prior anti-HER2 Regimens
Poziotinib Treatment in Patients With HER2-Positive Advanced Breast Cancer Who Have Received Prior anti-HER2 Regimens Open
Purpose Poziotinib is an irreversible pan-inhibitor of the human epidermal growth factor receptor (HER) that has shown acceptable tolerability and antitumor activity in phase I and II trials in patients with advanced solid tumors. In the p…
View article: 215P Impact of HER2 low on survival in patients treated with standard therapies in advanced breast cancer
215P Impact of HER2 low on survival in patients treated with standard therapies in advanced breast cancer Open
Breast cancer (BC) pioneered precision medicine with immunohistochemistry (IHC) defined subtypes and early advent of targeted therapies. Trastuzumab deruxtecan (T-DXd) has expanded traditional HER2 definitions to include HER2-low (H2L) tum…
View article: Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study Open
Background Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations. Methods This is a COVID-19 and Cancer Consortium (CCC19)…
View article: Immunogenicity of SARS-CoV-2 mRNA Vaccines in Patients with Cancer: Findings from an International Collaborative Cohort Study
Immunogenicity of SARS-CoV-2 mRNA Vaccines in Patients with Cancer: Findings from an International Collaborative Cohort Study Open
Patients with cancer experience higher burden of SARS-CoV-2 infection, disease severity, complications, and mortality, compared to the general population. SARS-CoV-2 mRNA vaccines have shown to be highly effective in clinical trials; howev…
View article: CTNI-07. DELIVERY AND ACTIVITY OF SN-38 BY SACITUZUMAB GOVITECAN IN CNS TUMORS
CTNI-07. DELIVERY AND ACTIVITY OF SN-38 BY SACITUZUMAB GOVITECAN IN CNS TUMORS Open
BACKGROUND Sacituzumab Govitecan (SG, TRODELVY™) is an antibody drug conjugate, with payload and linker characteristics preferable for CNS delivery. SG utilizes a pH hydrolysable linker, allowing SN-38 to be released at the tumor site. SN-…
View article: Additional file 2 of ERα-related chromothripsis enhances concordant gene transcription on chromosome 17q11.1-q24.1 in luminal breast cancer
Additional file 2 of ERα-related chromothripsis enhances concordant gene transcription on chromosome 17q11.1-q24.1 in luminal breast cancer Open
Additional file 2: Table S1. Frequencies of dense-ERα-binding-site related chromosomal rearrangements in five targeted regions. Table S2. Primer sequences used in Nanopore sequencing. Table S3. Primer sequences used in CRISPR/Cas9 experime…
View article: Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer
Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer Open
Unlike estrogen receptor α (ERα) that predominantly promotes hormone-dependent breast tumor growth, ERβ exhibits antitumor effects in a variety of cancer types. We recently identified a phosphotyrosine residue in ERβ, but not ERα, that dic…